Lumito (LUMITO) Q3 2025 earnings summary

Executive summary

• Achieved key milestones in commercialization of SCIZYS platform, including strategic partnerships and increased market presence in Q3 2025.

• Entered production and quality agreement with Optronic AB to scale manufacturing.

• Concept Life Sciences and Truly Labs integrated SCIZYS technology into their offerings after successful pilot studies.

• Strengthened financial position through a rights issue, raising approximately 36 MSEK to support commercialization.

• Selected for Business Sweden's Catalyst 2025 program, supporting UK market entry.

Financial highlights

• Q3 2025 net sales were 0 TSEK (0 TSEK in Q3 2024); net loss after tax was -9,511 TSEK (-10,844 TSEK in Q3 2024).

• Earnings per share for Q3 were -0.04 SEK (-0.05 SEK in Q3 2024).

• Cash flow from operations in Q3 was -2,967 TSEK (-5,567 TSEK in Q3 2024).

• For the first nine months, net loss after tax was -32,589 TSEK (-26,088 TSEK in 2024); cash and cash equivalents at period end were 4,094 TSEK (26,170 TSEK in 2024).

Outlook and guidance

• Ongoing commercialization efforts for SCIZYS, with expanded partnerships and increased international visibility.

• Rights issue and option program provide financial runway for continued growth and expansion.